On July 2, 2025, Lixte Biotechnology Holdings, Inc. closed a private placement, issuing 59,552 shares of common stock, 2,322,532 pre-funded warrants, 6,355,214 common stock warrants, and 3,573,130 preferred shares, raising approximately $4 million initially, with a total expected gross of $5 million. This financing aims to strengthen the company's equity above $2.5 million as it awaits Nasdaq compliance determination.